The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 40 | — | 20.1x | Near average | |
Growth | 7 | -75.9% | 5.6% | Below average | |
Quality | 35 | -271.4% | 7.6% | Near average | |
Safety | 48 | 0.2x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
CytomX Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy CytomX Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The price forecast for CytomX stock has stabilized at an average target of 10.71 dollars, representing a significant premium compared to the current price (3.76 dollars). The past 30 days have seen no adjustments in analyst targets or the number of coverages, indicating a state of anticipation awaiting new catalysts. However, there is a clear dispersion in estimates between the low of 6 dollars and the high of 16 dollars, reflecting high uncertainty regarding the stock's fair value.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.